SCHEMBL18239342

SCHEMBL18239342

CC(C)(C)OC(=O)N[C@H]1CCN(c2ncccn2)C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.55
PDE10A Q9Y233 4/20 0.53
CKS1B P61024 1/20 0.53
SKP1 P63208 1/20 0.53
SKP2 Q13309 1/20 0.53
CTSK P43235 2/20 0.52
PIM1 P11309 1/20 0.50
PIM3 Q86V86 1/20 0.50
PIM2 Q9P1W9 1/20 0.50
BTK Q06187 2/20 0.48
JAK3 P52333 1/20 0.48
MAP4K4 O95819 2/20 0.48
SUV39H2 Q9H5I1 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
SYK P43405 1/20 0.45
CYP2C9 P11712 1/20 0.45
HSD11B1 P28845 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28138962 0.93 BTK (0.57) GPR119PDE10ACTSKBTKJAK3
SCHEMBL28138963 0.93 BTK (0.57) GPR119PDE10ACTSKBTKJAK3
SCHEMBL4954279 0.92 GPR119 (0.61) GPR119PDE10ACKS1BSKP1SKP2
SCHEMBL21227878 0.89 PDE10A (0.50) GPR119PDE10ACKS1BSKP1SKP2
SCHEMBL20373261 0.88 PDE10A (0.50) PDE10ACKS1BSKP1SKP2CTSK
SCHEMBL17309220 0.88 PDE10A (0.50) PDE10ACKS1BSKP1SKP2CTSK
SCHEMBL951253 0.86 PDE10A (0.50) PDE10ACKS1BSKP1SKP2CTSK
SCHEMBL951251 0.86 PDE10A (0.50) PDE10ACKS1BSKP1SKP2CTSK
SCHEMBL31271961 0.86 PDE10A (0.50) PDE10ACKS1BSKP1SKP2CTSK
SCHEMBL15191231 0.86 MAP4K4 (0.50) PDE10ACKS1BSKP1SKP2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-05-31 US disclosed
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-05-31 US disclosed
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-05-31 US disclosed
WO-2016180536-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2016-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148429-A1 SUBSTITUTED QUINOXALINE DERIVATIVES BRCA1, NQO2, NQO1 GPR119 2823/4885PDE10A 4424/4885CKS1B 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.